Abstract
Resveratrol, a polyphenol found in grapes and wine, is considered a potential cancer chemopreventive agent. Resveratrol has been shown to induce transcription via both ERalpha and ERbeta. We observed significantly lower tumor growth, decreased angiogenesis, and increased apoptotic index in ERalpha- ERbeta+ MDA-MB-231 tumors in resveratrol-treated nude mice compared with controls. In vitro we found a significant increase in apoptosis in resveratrol-treated MDA-MB-231 cells in addition to significantly reduced extracellular levels of VEGF. This study supports the potential use of resveratrol as a chemotherapeutic agent in breast cancers.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / pathology
-
Adenocarcinoma / prevention & control*
-
Animals
-
Anticarcinogenic Agents / pharmacology*
-
Apoptosis / drug effects*
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / pathology
-
Breast Neoplasms / prevention & control*
-
Estrogen Receptor alpha
-
Estrogen Receptor beta
-
Female
-
Humans
-
Mice
-
Mice, Nude
-
Neovascularization, Pathologic*
-
Resveratrol
-
Stilbenes / pharmacology*
-
Transplantation, Heterologous
-
Vascular Endothelial Growth Factor A / biosynthesis
Substances
-
Anticarcinogenic Agents
-
Estrogen Receptor alpha
-
Estrogen Receptor beta
-
Stilbenes
-
Vascular Endothelial Growth Factor A
-
Resveratrol